After Flexion Therapeutics announced that the FDA has extended its review of the Supplemental New Drug Application to update Zilretta's label for repeat administration, Benchmark analyst Bruce Jackson said he continues to believe the company will get expanded labeling, "just not as rapidly as anticipated." Noting that the FDA has not asked for any additional clinical data and informed the company that it expects to complete the review in "the coming weeks," Jackson reiterated his Buy rating on Flexion shares, which are down about 5% in pre-market trading.